Characterization of the pharmacokinetics of bisantrene (NSC-337766) John G. KuhnThomas M. LuddenDaniel D. Von Hoff Clinical Pages: 253 - 258
The treatment of acute leukemia with continuous infusion L-Alanosine James K. WeickBill L. TranumFrancis S. Morrison Clinical Pages: 249 - 252
Effect of 2,3-dihydro-1H-imidazo [1,2-b]pyrazole (IMPY) on the metabolism of human red cells Arthur L. Sagone Jr.James A. NeidhartRose Marie Husney Clinical Pages: 243 - 248
A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma James C. ArseneauJanet M. WolterJohn C. Ruckdeschel Clinical Pages: 239 - 242
Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease William A. T. Knight IIICarol FabianCharles A. Coltman Jr. Clinical Pages: 235 - 237
Spirogermanium: A new investigational drug of novel structure and lack of bone marrow toxicity Milan SlavikOscar BlancJoan Davis Clinical Pages: 225 - 234
Pharmacokinetic study of methyl glyoxal-bis-guanylhydrazone (methyl-GAG) Milan SlavikThomas ClouseRobert C. Eschbach Preclinical Pages: 219 - 224
Correlation of the structure of amino-substituted anthraquinones to cytotoxicity in cultured Chinese hamster cells Bruce F. KimlerC. C. ChengMary L. Barnes Preclinical Pages: 213 - 218
Structure-activity relationship of 1-propargyl-5-halopyrimidin-2-ones John M. DornishReidar Oftebro Preclinical Pages: 203 - 211
The lethal activity and repair inhibition capacity of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea B. DrewinkoL. -Y. Yang Preclinical Pages: 197 - 202
Phase II study of Baker's antifol (triazinate, TZT, NSC 139, 105) in advanced carcinoma of the ovary James C. ArseneauBrian BundyJackson Beecham Clinical Pages: 185 - 188
Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group William A. Knight IIIDaniel D. Von HoffStephen E. Jones Clinical Pages: 181 - 184
Phase I trial of aclacinomycin-A Chatchada KaranesJohn D. YoungLaurence H. Baker Clinical Pages: 173 - 179
Phase I clinical trial of a new anthracycline: 4′-o-tetrahydropyranyl adriamycin Makoto OgawaHiroaki MiyamotoHiroshi Nakada Clinical Pages: 169 - 172
Phase I study of 4-demethoxydaunorubicin Valeria BonfanteLaura FerrariGianni Bonadonna Clinical Pages: 161 - 168
Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents Robert T. DorrDavid S. Alberts Clinical Pages: 151 - 159
Effects of harringtonine in combination with acivicin, adriamycin, L-asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1 Tsuyoshi OkanoTakao OhnumaHan Jui Preclinical Pages: 145 - 150
Comparative cytotoxicity of adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system John D. CowanDaniel D. Von HoffGary M. Clark Preclinical Pages: 139 - 144
In vitro cellular characteristics and survival responses of human astrocytoma clones to chloroethyl-nitrosoureas and dianhydrogalactitol Norma H. RubinCacilda CasartelliS. C. Barranco Preclinical Pages: 129 - 137
Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs S. C. BarrancoC. M. Townsend Jr.W. R. Boerwinkle Preclinical Pages: 117 - 127
Inhibitory activity of diarylamidine derivatives on murine leukemia L1210 cell growth Jan BalzariniErik de ClercqOtto Dann Preclinical Pages: 103 - 115
Phase II evaluation of MGBG in non-small cell carcinoma of the lung Ralph B. VanceWilliam A. Knight IIIAlbert F. LoBuglio Clinical Pages: 89 - 93
Anaphylactoid reactions associated with bisantrene infusions J. William MyersDaniel D. Von HoffRobert Pocelinko Clinical Pages: 85 - 88
Mitoxantrone hydrochloride (NSC-310739) in lymphoma Charles A. Coltman Jr.Terri M. McDanielDaniel D. Von Hoff Clinical Pages: 65 - 70
Pharmacokinetics of 4′-epi-doxorubicin in man H. WeenenJ. LankelmaH. M. Pinedo Clinical Pages: 59 - 64
Pharmacokinetics of 5,6-dihydro-5-azacytidine (NSC-264880) in the foxhound Louis MalspeisHaiyung ChengAlfred E. Staubus Preclinical Pages: 47 - 58
The human tumor cloning assay in cancer drug development Peter AgreThomas E. Williams Preclinical Pages: 33 - 45
Application of a microsomal drug activation system in a human tumor cloning assay Hans-Robert MetelmannDaniel D. Von Hoff Preclinical Pages: 27 - 32
Comparative in vitro antitumor activity of homoharringtonine and harringtonine against clonogenic human tumor cells T. L. JiangR. H. LiuS. E. Salmon Preclinical Pages: 21 - 25
Survival and cell cycle kinetics responses of Chinese hamster ovary cells, and clones of human adenocarcinoma of the stomach and astrocytoma to diaziquone (AZQ) in vitro S. C. BarrancoG. A. SchechterN. H. Rubin Preclinical Pages: 11 - 20
Activity of two phase I drugs N-methylformamide (NSC-3051) and Echinomycin (NSC-526417) against fresh surgical explants of human tumors in the 6-day subrenal capsule (SRC) assay William R. CobbArthur E. BogdenDoreen J. LePage Preclinical Pages: 5 - 9
